VNS Therapy Receives FDA Approval for Expanded MRI Labeling

This Week’s News in Review

This Week's News in Review! Medical Device News Magazine keeps our readers up-to-date on breaking industry news! Learn how Medical Device News Magazine can help...

New Research Shows Nearly Half of Elderly Suffer Decreased Mobility During Lockdown

In a survey of UK adults with parents over the age of 75, while over half (52%) of respondents remain worried about their parents catching Covid, 48 percent are concerned about parental loneliness, and 46 percent about their parents falling alone and not being able to get up or get help. This figure remained high even among those whose parents are in care homes, with 37% of respondents still most concerned about parents falling over.

American College of Cardiology Names Ravee Kurian COO/CFO

Kurian comes to ACC following a 20-year stint at Publicis Sapient, a leading technology and communications consultancy, where he led critical and sensitive digital transformation initiatives for Fortune 500 and U.S. federal clients.

LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, announced today that its latest VNS Therapy® systems (“VNS Therapy”) received FDA approval for expanded MRI labeling, affirming VNS Therapy as the only epilepsy device approved by the FDA for MRI scans. This FDA approval ensures VNS Therapy patients with the latest technology may visit any MRI center in the U.S. and have access to more than 90 percent of scans routinely performed on patients with epilepsy.

Damien McDonald, LivaNova’s Chief Executive Officer: “Our dedication to innovation has enabled LivaNova to remove a barrier for people with drug-resistant epilepsy who already have, or desire to have, the latest VNS Therapy technology based on its proven ability to deliver more seizure-free moments.” “Previously, our labeling allowed patients to obtain MRI scans only with the use of special MRI equipment that was not readily accessible. Now, this new approval simplifies the process and increases access of patients with our latest technology to any MRI center of their choice for the scans they need.”

Currently, AspireHC® and AspireSR® models of VNS Therapy technology provide for this expanded MRI access, enabling patients to obtain high-quality MRI scans and optimize treatment. Additional benefits include:

• improving ease of use and access to care

• eliminating the need for special MRI equipment

• providing comprehensive treatment throughout a patient’s lifetime

Jason Richey, LivaNova’s President of North America & General Manager of the Neuromodulation franchise states, “The FDA’s approval to expand our MRI labeling changes the landscape for device-based epilepsy therapies. “This further differentiates our technology from other epilepsy treatment options and adds a new dimension in our ability to support patients’ long-term treatment plans,” added Richey.

To date, VNS Therapy—a minimally invasive treatment designed to prevent seizures before they start and stop them if they do—has been used by more than 100,000 patients worldwide. More than one in three people with epilepsy has drug-resistant seizures, meaning seizures persist in spite of treatment with antiepileptic medications.1 It is estimated that approximately one million people suffer from drug-resistant epilepsy in the U.S. alone.

Reference

1. Kwan P., Brodie M.J. New England Journal of Medicine. 2000;342:314-19.

spot_img

DON'T MISS

Dr Jonathan Slotkin Appointed to Peer Well Board of Directors

Alongside the appointment, PeerWell is launching its new clinical practice, PeerWell Health.

Zimmer Biomet Announces New Appointments to Executive Leadership Team

Wilfred van Zuilen Appointed as President of Europe, Middle East and Africa. Nitin Goyal, M.D. Appointed to Newly Created Role of Chief Science, Technology and Innovation Officer.

Subscribe to Medical Device News Magazine here.

Related Articles